U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07640737) titled 'AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)' on June 03.
Brief Summary: A phase 2 Study Evaluating the Efficacy and Safety of Single Agent AUR103 Calcium in Patients with Advanced, Well or Moderately differentiated Neuroendocrine Tumours.
This is a Proof of Concept (PoC) Phase 2 study of AUR103 calcium in patients with advanced, well or moderately differentiated neuroendocrine tumours.
The main objective is to evaluate the efficacy of AUR103 calcium in patients with well or moderately differentiated neuroendocrine tumors.
Patients with relapsed/refractory well or moderately differentiated neuroendocrine tum...